KRAS and colorectal carcinoma: Among RAS mutations, the most frequently found oncogenic driver is KRAS mutations, observed in almost 97.7% of pancreatic ductal adenocarcinoma, 44.7% of colorectal carcinoma, and 30.9% of lung carcinoma cases [19].